{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:11:23Z","timestamp":1793340683368,"version":"4.5.0"},"reference-count":204,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005681","name":"Genesis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005681","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022344","name":"InflaRx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022344","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018747","name":"SkylineDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.04.018","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T08:09:48Z","timestamp":1653379788000},"page":"256-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":264,"special_numbering":"C","title":["European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022"],"prefix":"10.1016","volume":"170","author":[{"given":"Claus","family":"Garbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Basset-Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Forsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kelleners-Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilios","family":"Lallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodhan","family":"Lytvynenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moreno-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"Van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.04.018_bib1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.018_bib2","first-page":"325","article-title":"Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report","volume":"17","author":"Saiag","year":"2007","journal-title":"Eur J Dermatol : EJD."},{"key":"10.1016\/j.ejca.2022.04.018_bib3","first-page":"218","article-title":"Surgical standards in the primary care of melanoma patients","volume":"26","author":"Hauschild","year":"2003","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2022.04.018_bib4","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.amjsurg.2005.08.020","article-title":"Is incisional biopsy of melanoma harmful?","volume":"190","author":"Martin","year":"2005","journal-title":"Am J Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clindermatol.2009.06.013","article-title":"Incisional biopsy and melanoma prognosis: Facts and controversies","volume":"28","author":"Pflugfelder","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib6","doi-asserted-by":"crossref","first-page":"6168","DOI":"10.1245\/s10434-021-09866-3","article-title":"Impact of shave biopsy on diagnosis and management of cutaneous melanoma: a systematic review and meta-analysis","volume":"28","author":"Ahmadi","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.6004\/jnccn.2009.0020","article-title":"Melanoma","volume":"7","author":"Coit","year":"2009","journal-title":"J Natl Compr Cancer Netw : JNCCN."},{"key":"10.1016\/j.ejca.2022.04.018_bib8","series-title":"Clinical practice guidelines for the management of melanoma in Australia and New Zealand","article-title":"Australian cancer network melanoma guidelines revision working party","year":"2008"},{"issue":"10","key":"10.1016\/j.ejca.2022.04.018_bib9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0151-9638(05)79450-3","volume":"132","author":"Negrier","year":"2005","journal-title":"Annales de dermatologie et de venereologie"},{"key":"10.1016\/j.ejca.2022.04.018_bib10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09883.x","article-title":"Revised U.K. guidelines for the management of cutaneous melanoma 2010","volume":"163","author":"Marsden","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0b013e3282f702bf","article-title":"Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting","volume":"18","author":"Garbe","year":"2008","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(15)00482-9","article-title":"Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial","volume":"17","author":"Hayes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ctrv.2015.10.013","article-title":"Surgical excision margins in primary cutaneous melanoma: a meta-analysis and Bayesian probability evaluation","volume":"42","author":"Wheatley","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2022.04.018_bib14","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(11)61546-8","article-title":"2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial","volume":"378","author":"Gillgren","year":"2011","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejca.2022.04.018_bib15","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ejso.2021.02.025","article-title":"Surgical excision margins in primary cutaneous melanoma: a systematic review and meta-analysis","volume":"47","author":"Hanna","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib16","series-title":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge des Melanoms, Langversion 3.1","author":"Onkologie","year":"2018"},{"issue":"Suppl 6","key":"10.1016\/j.ejca.2022.04.018_bib17","first-page":"1","article-title":"Malignant melanoma S3-guideline \u201cdiagnosis, therapy and follow-up of melanoma\u201d","volume":"11","author":"Pflugfelder","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2022.04.018_bib18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2133.2005.07068.x","article-title":"Conventional histology vs. three-dimensional histology in lentigo maligna melanoma","volume":"154","author":"Moehrle","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib19","first-page":"Cd010308","article-title":"Interventions for melanoma in situ, including lentigo maligna","author":"Tzellos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2022.04.018_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjd.14325","article-title":"Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision","volume":"174","author":"de Vries","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ad.2011.12.009","article-title":"Conventional surgery compared with slow Mohs micrographic surgery in the treatment of lentigo maligna: a retrospective study of 62 cases","volume":"103","author":"Hilari","year":"2012","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"10.1016\/j.ejca.2022.04.018_bib22","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/DSS.0000000000003268","article-title":"Systematic review of technical variations for Mohs micrographic surgery for melanoma","volume":"47","author":"Krausz","year":"2021","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jdv.14085","article-title":"A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures","volume":"31","author":"Tio","year":"2017","journal-title":"J Eur Acad Dermatol Venereol : JEADV"},{"key":"10.1016\/j.ejca.2022.04.018_bib24","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","article-title":"Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type","volume":"72","author":"Swetter","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib25","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjd.20407","article-title":"Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna","volume":"185","author":"Lallas","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib26","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/archderm.144.7.943","article-title":"Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients","volume":"144","author":"Buettiker","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/SAP.0b013e31816714c8","article-title":"Topical imiquimod therapy for lentigo maligna","volume":"61","author":"Mahoney","year":"2008","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00042728-200802000-00002","article-title":"Treatment of lentigo maligna with imiquimod before staged excision","volume":"34","author":"Cotter","year":"2008","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib29","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamadermatol.2017.3114","article-title":"Correlation of handheld reflectance confocal microscopy with radial video mosaicing for margin mapping of lentigo maligna and lentigo maligna melanoma","volume":"153","author":"Yelamos","year":"2017","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.ejca.2022.04.018_bib30","first-page":"366","article-title":"\u201cFunctional\u201d surgery in subungual melanoma","volume":"29","author":"Moehrle","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib31","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/00000478-199912000-00006","article-title":"Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation","volume":"23","author":"Breuninger","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2022.04.018_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jso.20305","article-title":"Mohs micrographic surgery in the treatment of lentigo maligna and melanoma","volume":"94","author":"Temple","year":"2006","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib34","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.ejca.2022.04.018_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.soc.2006.10.013","article-title":"Sentinel node mapping for melanoma: results of trials and current applications","volume":"16","author":"Thompson","year":"2007","journal-title":"Surg Oncol Clin"},{"key":"10.1016\/j.ejca.2022.04.018_bib36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/01.sla.0000181092.50141.fa","article-title":"Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial","volume":"242","author":"Morton","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib37","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2017.75.7724","article-title":"Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American society of clinical oncology and society of surgical oncology clinical practice guideline update","volume":"36","author":"Wong","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib39","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1245\/s10434-016-5137-z","article-title":"Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis","volume":"23","author":"Cordeiro","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib40","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib44","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1245\/s10434-020-08478-7","article-title":"Adjuvant therapy is effective for melanoma patients with a positive sentinel lymph node biopsy who Forego completion lymphadenectomy","volume":"27","author":"Farrow","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1245\/s10434-021-10775-8","article-title":"Adjuvant therapy for stage III melanoma without immediate completion lymph node dissection","volume":"29","author":"Torphy","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00000658-199110000-00013","article-title":"Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic","volume":"214","author":"Morton","year":"1991","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib47","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00008390-199910000-00009","article-title":"Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study","volume":"9","author":"Lienard","year":"1999","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1245\/s10434-011-2030-7","article-title":"20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters","volume":"19","author":"Deroose","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib50","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/bjc.2012.306","article-title":"Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis","volume":"107","author":"Weide","year":"2012","journal-title":"British journal of cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jtcvs.2006.08.065","article-title":"Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma","volume":"133","author":"Petersen","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.ejca.2022.04.018_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejso.2008.04.011","article-title":"Surgery for melanoma metastases of the gastrointestinal tract: indications and results","volume":"35","author":"Sanki","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib53","doi-asserted-by":"crossref","first-page":"634","DOI":"10.47102\/annals-acadmedsg.V39N8p634","article-title":"Surgical metastasectomy in\u00a0AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases","volume":"39","author":"Chua","year":"2010","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ejca.2022.04.018_bib54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21903","article-title":"Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes","volume":"104","author":"Wasif","year":"2011","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib55","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib56","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1046\/j.1365-2133.2002.04750.x","article-title":"A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays","volume":"146","author":"Farshad","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2022.04.018_bib57","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","article-title":"Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial","volume":"13","author":"Burmeister","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib58","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(15)00187-4","article-title":"Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02\/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial","volume":"16","author":"Henderson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib59","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.22988","article-title":"A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma","volume":"110","author":"Olivier","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib60","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0360-3016(88)90118-6","article-title":"Palliative radiotherapy for metastatic malignant melanoma: brain metastases, bone metastases, and spinal cord compression","volume":"15","author":"Rate","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.018_bib61","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0360-3016(81)90007-9","article-title":"The results of different fractionation schemes in the palliative irradiation of metastatic melanoma","volume":"7","author":"Katz","year":"1981","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2022.04.018_bib62","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1097-0142(19880115)61:2<243::AID-CNCR2820610207>3.0.CO;2-K","article-title":"Analysis of dose fractionation in the palliation of metastases from malignant melanoma","volume":"61","author":"Konefal","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib63","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/00008390-199912000-00012","article-title":"Radiotherapy as palliative treatment for metastatic melanoma","volume":"9","author":"Kirova","year":"1999","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib64","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib65","doi-asserted-by":"crossref","unstructured":"Tawbi H. Safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with advanced melanoma(MEL) metastatic to the brain: Initial Results From Phase 2 CheckMate 204. SMR2016.","DOI":"10.1200\/JCO.2017.35.15_suppl.9507"},{"key":"10.1016\/j.ejca.2022.04.018_bib66","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2022.04.018_bib67","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.semradonc.2014.07.003","article-title":"Current clinical trials testing combinations of immunotherapy and radiation","volume":"25","author":"Crittenden","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib68","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","article-title":"Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data","volume":"130","author":"Lehrer","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2018.12.023","article-title":"Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases","volume":"110","author":"Rauschenberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib70","first-page":"1","article-title":"Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review","author":"Tagliaferri","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ejca.2022.04.018_bib71","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CMR.0000000000000761","article-title":"Combination of radiotherapy and targeted therapy for melanoma brain metastases: a systematic review","volume":"31","author":"Ge","year":"2021","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib72","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.prro.2021.04.002","article-title":"Radiation therapy for brain metastases: a systematic review","volume":"11","author":"Garsa","year":"2021","journal-title":"Practical radiation oncology"},{"key":"10.1016\/j.ejca.2022.04.018_bib73","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib74","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib75","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib76","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib77","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib78","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2022.04.018_bib79","first-page":"S1283","article-title":"LBA3 PR - pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: efficacy and safety results from the KEYNOTE-716 double-blind phase III trial","volume":"32","author":"Luke PR","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib80","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejca.2022.04.018_bib81","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1158\/1078-0432.CCR-21-0793","article-title":"Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules","volume":"27","author":"Long","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib82","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1200\/JCO.1998.16.4.1425","article-title":"Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group","volume":"16","author":"Pehamberger","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib83","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/annonc\/mdn001","article-title":"Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis","volume":"19","author":"Garbe","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib84","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","article-title":"Final results of the EORTC 18871\/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1200\/JCO.2004.03.185","article-title":"Adjuvant interferon in high-risk melanoma: the AIM HIGH Study\u2013United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma","volume":"22","author":"Hancock","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib86","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0140-6736(01)06068-8","article-title":"Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial","volume":"358","author":"Cascinelli","year":"2001","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejca.2022.04.018_bib87","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1054\/bjoc.2000.1623","article-title":"Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study","volume":"84","author":"Cameron","year":"2001","journal-title":"British journal of cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib88","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib89","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(97)12445-X","article-title":"Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma","volume":"351","author":"Grob","year":"1998","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejca.2022.04.018_bib90","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S1470-2045(10)70288-6","article-title":"Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial","volume":"12","author":"Hansson","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib91","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejca.2022.04.018_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib93","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1200\/JCO.1995.13.11.2776","article-title":"Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma","volume":"13","author":"Creagan","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ejca.2022.04.018_bib95","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib97","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib98","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib99","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1200\/JCO.2020.38.15_suppl.10000","article-title":"Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial at three-year median follow-up","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2022.04.018_bib100","first-page":"S1142","article-title":"LBA46 - pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial","volume":"31","author":"Eggermont CUB","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib101","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1200\/JCO.2021.39.15_suppl.9500","article-title":"Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG\/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma","volume":"39","author":"Eggermont","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib102","series-title":"AACR Annual Meeting","article-title":"Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D\/IV melanoma (CheckMate 915)","author":"Long","year":"2021"},{"key":"10.1016\/j.ejca.2022.04.018_bib103","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib104","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2020.38.15_suppl.10001","article-title":"Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600\u2013mutant melanoma: Five-year analysis of COMBI-AD","volume":"38","author":"Hauschild","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib105","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1200\/JCO.2021.39.15_suppl.9525","article-title":"Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): primary results of COMBI-APlus","volume":"39","author":"Atkinson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib106","first-page":"JCO1801219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma","author":"Hauschild","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib107","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib108","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib109","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2021.39.15_suppl.9502","article-title":"Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma","volume":"39","author":"Amaria","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib110","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients\u00a0with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib112","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Melanoma. The Lancet."},{"key":"10.1016\/j.ejca.2022.04.018_bib113","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers12041027","article-title":"Primary resistance to PD-1-based immunotherapy-A study in 319 patients with stage IV melanoma","volume":"12","author":"Amaral","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.04.018_bib114","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/jco.2007.25.18_suppl.8508","article-title":"An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites","author":"Morton","year":"2007","journal-title":"J clinic oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.2804","article-title":"A new era: melanoma genetics and therapeutics","volume":"223","author":"Ko","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2022.04.018_bib116","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib117","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.ejca.2022.04.018_bib118","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.04.018_bib119","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib120","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib121","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib122","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib123","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib124","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib125","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib126","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib127","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and\u00a0clinical safety of 480 mg every 4 weeks flat-dosing schedule\u00a0in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib128","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2018.36.15_suppl.3062","article-title":"A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation","volume":"36","author":"Lala","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib131","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib132","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2021.39.15_suppl.9506","article-title":"CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma","volume":"39","author":"Wolchok","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib133","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib134","doi-asserted-by":"crossref","first-page":"viii737","DOI":"10.1093\/annonc\/mdy424.057","article-title":"Initial results from a phase IIIb\/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)","volume":"29","author":"Lebb\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib135","doi-asserted-by":"crossref","first-page":"9516","DOI":"10.1200\/JCO.2021.39.15_suppl.9516","article-title":"Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: three-year results of CheckMate 511","volume":"39","author":"Lebbe","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib136","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib137","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib138","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib139","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib140","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib141","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib142","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib143","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib144","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib145","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-Year outcomes with cobimetinib plus vemurafenib in BRAF (V600) mutation-positive advanced melanoma: extended follow-up of the coBRIM study","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib146","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2021.39.15_suppl.9507","article-title":"Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma","volume":"39","author":"Dummer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib147","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib148","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib149","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib150","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/jco.2014.32.15_suppl.9011","volume":"32","author":"Long","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib151","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib152","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib153","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2018.36.15_suppl.9504","article-title":"Overall survival in COLUMBUS: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma","volume":"36","author":"Dummer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.ejca.2022.04.018_bib154","doi-asserted-by":"crossref","first-page":"iv392","DOI":"10.1093\/annonc\/mdu344.46","article-title":"1130TiP- NEMO: a phase 3 trial OF binimetinib (MEK162) versus dacarbazine IN patients with advanced NRAS-mutant melanoma who are untreated or have progressed after any number of immunotherapy regimens","volume":"25","author":"Dummer","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2020.02.021","article-title":"Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019","volume":"130","author":"Ugurel","year":"2020","journal-title":"Eur J Cancer"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2022.04.018_bib156","first-page":"S1283","article-title":"LBA40 - SECOMBIT: the best sequential approach with combo immunotherapy ipilimumab (I)\/nivolumab (N) and combo target therapy encorafenib (E)\/binimetinib (B) in patients with BRAF mutated metastatic melanoma: a phase II randomized study","volume":"32","author":"Ascierto","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib157","doi-asserted-by":"crossref","first-page":"356154","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase III trial\u2014ECOG-ACRIN EA6134","volume":"39","author":"Atkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2022.04.018_bib158","first-page":"S867","article-title":"1037O - MASTERKEY-265: a phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB\u2013IVM1c melanoma (MEL)","volume":"32","author":"Gogas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib159","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib160","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503","article-title":"Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: primary phase III results from RELATIVITY-047 (CA224-047)","volume":"39","author":"Lipson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2022.04.018_bib161","doi-asserted-by":"crossref","first-page":"S867","DOI":"10.1016\/j.annonc.2021.08.1421","article-title":"1036O - relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIVITY-047","volume":"32","author":"Hodi HAT","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib162","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2021.11.022","article-title":"Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis","volume":"162","author":"Goldinger","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib163","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdq438","article-title":"Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma","volume":"22","author":"Bedikian","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib164","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.04.030","article-title":"Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032)","volume":"47","author":"Patel","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib165","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib166","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib167","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02985163","article-title":"Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: a randomized phase II study","volume":"6","author":"Ringborg","year":"1989","journal-title":"Med Oncol Tumor Pharmacother"},{"key":"10.1016\/j.ejca.2022.04.018_bib168","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200104000-00015","article-title":"Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients","volume":"11","author":"Chiarion Sileni","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib169","first-page":"458","article-title":"Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma","volume":"13","author":"Young","year":"2001","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib170","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.1995.13.4.910","article-title":"Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma","volume":"13","author":"Bleehen","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib171","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00684883","article-title":"Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma","volume":"25","author":"Jacquillat","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2022.04.018_bib172","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00008390-200302000-00016","article-title":"A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma","volume":"13","author":"Mornex","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib173","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/cncr.21611","article-title":"Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma","volume":"106","author":"Rao","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib174","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/1097-0142(19880915)62:6<1061::AID-CNCR2820620607>3.0.CO;2-X","article-title":"Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the EORTC malignant melanoma cooperative group","volume":"62","author":"Verschraegen","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib176","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2022.04.018_bib177","first-page":"S867","article-title":"1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)","volume":"32","author":"Margolin HAT","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib178","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508","article-title":"Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets)","volume":"39","author":"Long","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib179","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib180","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1093\/annonc\/mdu266","article-title":"On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases","volume":"25","author":"Gaudy-Marqueste","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib181","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoncol.2018.4610","article-title":"Comparison of local control of brain metastases with stereotactic radiosurgery vs surgical resection: a secondary analysis of a randomized clinical trial","volume":"5","author":"Churilla","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib182","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000333","article-title":"Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG\u2217 study in 380 patients","volume":"8","author":"Amaral","year":"2020","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib183","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000497211","article-title":"Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis","volume":"42","author":"Galli","year":"2019","journal-title":"Oncology research and treatment"},{"key":"10.1016\/j.ejca.2022.04.018_bib184","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9600","article-title":"A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial)","volume":"37","author":"Gonzalez","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.ejca.2022.04.018_bib185","first-page":"S867","article-title":"1038MO - intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: preliminary results of the GEM1802\/EBRAIN-MEL phase II clinical trial","volume":"32","author":"Marquez-Rodas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib186","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib187","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib188","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.ejca.2022.04.018_bib189","doi-asserted-by":"crossref","first-page":"CT008","DOI":"10.1158\/1538-7445.AM2021-CT008","article-title":"Abstract CT008: lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up","volume":"81","author":"Chesney","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib190","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1200\/JCO.2021.39.15_suppl.9504","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: updated findings of LEAP-004","volume":"39","author":"Arance","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib191","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092359","article-title":"Distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients","volume":"12","author":"Hilke","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.04.018_bib192","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/CMR.0000000000000764","article-title":"Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis","volume":"31","author":"Cho","year":"2021","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2022.04.018_bib193","doi-asserted-by":"crossref","first-page":"602705","DOI":"10.3389\/fonc.2020.602705","article-title":"Immune checkpoint inhibitors in advanced acral melanoma: a systematic review","volume":"10","author":"Zheng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib194","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188602","article-title":"Variables that influence BRAF mutation probability: a next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma","volume":"12","author":"Gaiser","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2022.04.018_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/cells10092320","article-title":"Molecular markers and targets in melanoma","volume":"10","author":"Teixido","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2022.04.018_bib196","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2020.07.017","article-title":"Head and neck mucosal melanoma: the United Kingdom national guidelines","volume":"138","author":"Nenclares","year":"2020","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib197","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2020.04.030","article-title":"Ano-uro-genital mucosal melanoma UK national guidelines","volume":"135","author":"Smith","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib198","doi-asserted-by":"crossref","first-page":"10019","DOI":"10.1200\/JCO.2020.38.15_suppl.10019","article-title":"CheckMate 067: long-term outcomes in patients with mucosal melanoma","volume":"38","author":"Shoushtari","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.018_bib199","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/j.ejca.2015.07.013","article-title":"Uveal melanoma UK national guidelines","volume":"51","author":"Nathan","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib200","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejca.2022.04.018_bib201","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in\u00a0metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.04.018_bib202","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2022.04.018_bib203","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.annonc.2020.04.471","article-title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy","volume":"31","author":"Owen","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl_4","key":"10.1016\/j.ejca.2022.04.018_bib204","first-page":"S672","article-title":"1080MO - the value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition","volume":"31","author":"Versluis AMH","year":"2020","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:34Z","timestamp":1760733514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":204,"alternative-id":["S0959804922002283"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.018","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.008","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}